LUXEMBOURG and PARIS, Dec. 10, 2025 /PRNewswire/ -- FitLine is proud to announce a new partnership with Paris Basketball, the…
LEUVEN, BELGIUM – Euro NCAP’s independent assessment of the new CLA shows an outstanding safety performance with a five-star result…
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
December 05, 2025 08:00 ET | Source: Amneal Pharmaceuticals LLC Interim data show substantial improvements in “Good On” time compared…
DALLAS, Dec. 2, 2025 /PRNewswire/ -- On December 1, Cango Inc. (NYSE: CANG) ("Cango" or the "Company") announced its unaudited…
November 2025 global sales of 262,065 units, down 0.8% Y/yIn Korea, Kia sold 47,256 units, down 1.6% Y/yOutside of Korea,…